Overall, these findings provide a potential mechanism for the enduring effect of pathological inflammation on brain function in a common chronic progressive neurodegenerative disorder and suggest IGF2 levels could potentially be a useful predictive or diagnostic biomarker for Aβ42-targeted AD therapies. Here, IGF2 is linked to Alzheimer disease.